Page last updated: 2024-11-08

dihydrosphingosine 1-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dihydrosphingosine 1-phosphate: RN given refers to (R-(R*,S*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sphinganine 1-phosphate : A sphingoid 1-phosphate that is the monophosphorylated derivative of sphinganine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID644260
CHEMBL ID78494
CHEBI ID16893
SCHEMBL ID195872
MeSH IDM0168070

Synonyms (41)

Synonym
CBIOL_001741
CHEMBL78494
dihydros1p
gtpl2921
BIO1_000027
BIO1_001005
BIO1_000516
(2s,3r)-2-amino-3-hydroxyoctadecyl dihydrogen phosphate
sphinganine 1-(dihydrogen phosphate)
dihydrosphingosine-1-phosphate
CHEBI:16893 ,
1,3-octadecanediol, 2-amino-, 1-(dihydrogen phosphate), (2s,3r)- (9ci)
1,3-octadecanediol, 2-amino-, 1-(dihydrogen phosphate), (2s,3r)-
(2s,3r)-sphinganine 1-phosphate
1,3-octadecanediol, 2-amino-, 1-(dihydrogen phosphate), [r-(r*,s*)]-
c18-dihydrosphingosine 1-phosphate
1,3-octadecanediol, 2-amino-, 1-(dihydrogen phosphate), d-erythro- (8ci)
19794-97-9
C01120
sphinganine 1-phosphate
dihydrosphingosine 1-phosphate
LMSP01050002
dihydrosphingosine phosphate
sphinganine-phosphate
sphinganine-1-phosphate
NCGC00161366-01
BML3-D08
[(2s,3r)-2-amino-3-hydroxyoctadecyl] dihydrogen phosphate
2-amino-3-hydroxyoctadecyl dihydrogen phosphate
d-erythro-dihydro-d-sphingosine-1-phosphate
d-erythro-dihydrosphingosine 1-phosphate
108126-32-5
SCHEMBL195872
HB3871
AKOS030531313
dihydrosphingosine-1-phosphate, d-erythro
J-017108
Q27077062
HY-113116
DTXSID601313490
CS-0059613

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In our previous study, FB1 was confirmed to be toxic to both liver and kidneys, coupled with simultaneous elevation of sphinganine 1-phosphate."( Elevation of sphingoid base 1-phosphate as a potential contributor to hepatotoxicity in fumonisin B1-exposed mice.
Kim, DH; Lee, YM; Lee, YS; Oh, S; Yoo, HS; Yun, YP, 2007
)
0.34
" Two toxic targets (PRKCA, FASN), three effective targets (PLA2G10, PTGES, PLA2G1B), and four effective and toxic targets (PTGS1, PTGS2, PLA2G2A, ALOX5) were obtained by metabolomics combined with network analysis and network pharmacology."( Synchronous Investigation of the Mechanism and Substance Basis of Tripterygium Glycosides Tablets on Anti-rheumatoid Arthritis and Hepatotoxicity.
Gao, Y; Ge, J; Mou, F; Qian, Q; Su, S; Wang, Q; Wang, X; Xun, G; Zhang, H, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
sphingoid 1-phosphateA generic class of phosphosphingolipids, encompassing monophosphorylated derivatives of sphinganine, its homologues and stereoisomers, as well as the hydroxy and unsaturated derivatives of these compounds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Sphingolipid Metabolism2335
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Fabry Disease2335
Krabbe Disease2335
Sphingolipid metabolism (integrated pathway)1167
Sphingolipid metabolism overview415
Sphingolipid metabolism: integrated pathway163
sphingolipid metabolism020
Sphingolipid pathway315
Sphingolipids metabolism pathway063
Sphingolipid metabolism415

Bioassays (5)

Assay IDTitleYearJournalArticle
AID67968In vitro binding affinity towards Endothelial differentiation G-protein coupled receptor 3 in CHO cells using [3H]S1P as radioligand relative to SIP2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Syntheses of sphingosine-1-phosphate stereoisomers and analogues and their interaction with EDG receptors.
AID67966In vitro binding affinity towards Endothelial differentiation G-protein coupled receptor 1 in CHO cells using [3H]S1P as radioligand relative to SIP2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Syntheses of sphingosine-1-phosphate stereoisomers and analogues and their interaction with EDG receptors.
AID67970In vitro binding affinity towards Endothelial differentiation G-protein coupled receptor 5 in CHO cells using [3H]S1P as radioligand relative to SIP2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Syntheses of sphingosine-1-phosphate stereoisomers and analogues and their interaction with EDG receptors.
AID1346162Human S1P4 receptor (Lysophospholipid (S1P) receptors)2002Biochemical and biophysical research communications, Sep-27, Volume: 297, Issue:3
Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor.
AID1345173Human GPR63 (Class A Orphans)2003Cellular signalling, Apr, Volume: 15, Issue:4
Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.18)18.7374
1990's9 (10.59)18.2507
2000's38 (44.71)29.6817
2010's27 (31.76)24.3611
2020's10 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.48 (24.57)
Research Supply Index4.47 (2.92)
Research Growth Index5.76 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other84 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]